HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin

Table 4 Leukocyte and lymphocyte counts in hepatitis C virus chronically infected patients treated with interferon-α plus ribavirin

Groups		Control group	Group E6	Group E9	Group L6	Group L9
Total number of patients		30	16	16	15	15
Baseline leukocyte counts	mean ± SD	6.7 ± 2.1	7.0 ± 1.5	7.7 ± 2.3	6.4 ± 2.0	7.0 ± 2.2
	(Min; Max)	(3.5; 12.1)	(4.2; 9.0)	(3.8; 12.2)	(4.0; 11.1)	(2.0; 10.5)
Week 12 leukocyte counts	mean ± SD	4.5 ± 1.5	4.4 ± 1.8	5.0 ± 1.5	3.7 ± 0.9	4.7 ± 0.9
	(Min; Max)	(2.3; 9.0)	(2.3; 8.4)	(3.1; 7.3)	(2.7; 5.1)	(3.4; 6.8)
Week 48 leukocyte counts	mean ± SD	4.3 ± 1.3	3.6 ± 1.2	4.4 ± 1.5	3.7 ± 1.3	4.9 ± 0.9
	(Min; Max)	(2.5; 7.6)	(1.6; 6.7)	(2.3; 7.6)	(2.5; 6.6)	(2.9; 5.8)
Statistics (P value)1		< 0.001	0.001	< 0.001	0.001	0.013
Statistics (P value)2		< 0.010	0.001	0.001	0.001	0.023
Baseline lymphocyte counts	mean ± SD	37.8 ± 8.6	35.7 ± 7.6	33.7 ± 7.5	36.7 ± 10.7	37.6 ± 8.7
	(Min; Max)	(22.8; 58.8)	(21.8; 52.5)	(19.8; 53.8)	(18.3; 51.4)	(25.4; 50.7)
Week 12 lymphocyte counts	mean ± SD	38.2 ± 9.7	34.6 ± 6.9	30.5 ± 8.0	36.1 ± 9.5	36.5 ± 7.5
	(Min; Max)	(20.3; 52.9)	(22.0; 44.1)	(15.8; 47.4)	(22.5; 55.2)	(25.3; 52.0)
Week 48 lymphocyte counts	mean ± SD	32.0 ± 8.9	37.1 ± 8.3	31.2 ± 6.9	34.9 ± 11.3	33.1 ± 6.2
	(Min; Max)	(13.3; 57.8)	(19.5; 50.9)	(21.3; 45.0)	(19.8; 54.0)	(23.5; 42.3)
Statistics (P value)1		ns	ns	ns	ns	ns
Statistics (P value)2		0.004	ns	ns	ns	ns

¹Week 12 vs baseline in one group;

²Week 48 vs baseline in one group (Differences were considered significant when P < 0.05; Wilcoxon signed ranks test for leukocyte counts, Paired t test for lymphocyte counts). Results are given as 10⁹ cells/L in the case of leukocytes and as % in the case of lymphocytes. ns: Not significant.